Protocatechuic Acid Eye Wash for Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eye infections and inflammation, including conjunctivitis and blepharitis, face challenges such as microbial resistance, drug toxicity, irritation, and hypersensitivity, while contact lens care solutions lack beneficial effects on ocular tissues and undergo systemic absorption.
Innovation Solution
A solution comprising sterilized water and protocatechuic acid (PCA) is used to treat eye infections and inflammation, with optional inclusion of ciprofloxacin or norfloxacin, and a surfactant such as polyethylene glycol esters or polyoxyethylene-polyoxypropylene block copolymers for contact lens disinfection, providing anti-inflammatory, antibacterial, and antioxidant benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics and antivirals are used to treat eye infections, then microbial resistance develops, but treatment effectiveness is maintained initially
Solution Approach 1:
The patent changes the chemical parameter from conventional antibiotics to protocatechuic acid, a natural phenolic compound with broad-spectrum antimicrobial activity. This parameter change allows effective treatment of bacterial, viral, and fungal eye infections without inducing microbial resistance, as the acid works through multiple mechanisms including membrane disruption and enzyme inhibition rather than single-target antibiotic pathways
Solution Approach 2:
The invention combines protocatechuic acid with other complementary ingredients including antioxidants, anti-inflammatory agents, and surfactants in a multi-component ophthalmic solution. This composite formulation addresses multiple aspects of eye infections simultaneously - antimicrobial action, inflammation reduction, and tissue protection - while avoiding resistance development through the acid's broad mechanism of action
2Reliability
If topical antibiotics and steroids are applied to treat eye infections, then infection is controlled, but drug toxicity and irritation occur
Solution Approach 1:
The patent employs protocatechuic acid, a naturally occurring phenolic compound that is rapidly metabolized and eliminated by the body. This short-lived active ingredient provides effective antimicrobial and anti-inflammatory action during the treatment period but does not accumulate to toxic levels, unlike conventional antibiotics and steroids that can persist and cause toxicity with prolonged use
Solution Approach 2:
The ophthalmic solution uses protocatechuic acid as an intermediary substance that mediates between the need for strong antimicrobial activity and the requirement for tissue safety. The acid's natural origin and multiple biochemical pathways of action allow it to effectively combat infections while being converted to harmless metabolites, serving as a safe intermediary that avoids the toxicity issues of synthetic drugs
3Ease of manufacture
If contact lens care solutions are used for disinfection, then lenses are cleaned, but beneficial effects on ocular tissues are lacking
Solution Approach 1:
The patent formulates an ophthalmic solution with protocatechuic acid that serves multiple functions simultaneously: it acts as an effective lens cleaning and disinfecting agent while also providing direct therapeutic benefits to ocular tissues through its antimicrobial, anti-inflammatory, and antioxidant properties. This multi-functional formulation eliminates the need for separate lens care and eye treatment products
Solution Approach 2:
The invention merges the functions of contact lens care solution and ophthalmic medication into a single integrated formulation. The protocatechuic acid-based solution combines lens cleaning capabilities with therapeutic eye treatment, allowing the same product to both disinfect lenses and treat eye infections and inflammation, thereby providing beneficial effects on ocular tissues that conventional lens solutions lack
Data Source
AI summary
This disclosure provides a method of treating an infection or inflammation of an eye of a mammal including contacting an eye with a solution comprising sterilized water and protocatechuic acid. The protocatechuic acid may be between about 0.01 wt % and 1.25 wt % in the solution. The solution may include saline. The solution may include ciprofloxacin and/or norfloxacin. This disclosure further provides a method of disinfecting a contact lens including contacting a contact lens with a solution including protocatechuic acid. The solution may include a surfactant. The surfactant may include polyethylene glycol esters of fatty acids, coconut, polysorbate, polyoxyethylene or polyoxypropylene ethers of high alkanes C12-C18. The surfactant may include poly(oxypropylene)-poly(oxyethylene) adducts of ethylene diamine having a molecular weight about 7,500 to about 27,000 wherein at least about 40 weight percent of the adducts is poly(oxyethylene).